Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P10147
UPID:
CCL3_HUMAN
Alternative names:
G0/G1 switch regulatory protein 19-1; Macrophage inflammatory protein 1-alpha; PAT 464.1; SIS-beta; Small-inducible cytokine A3; Tonsillar lymphocyte LD78 alpha protein
Alternative UPACC:
P10147
Background:
C-C motif chemokine 3, also known as Macrophage inflammatory protein 1-alpha, plays a pivotal role in inflammatory responses and immune regulation. It binds to receptors CCR1, CCR4, and CCR5, showcasing its versatility in cell signaling and its critical function in the immune system's response to pathogens.
Therapeutic significance:
Understanding the role of C-C motif chemokine 3 could open doors to potential therapeutic strategies. Its ability to inhibit various strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV) underscores its therapeutic potential in viral infection management and immune modulation.